Skip to main content
Have a personal or library account? Click to login
What is a Therapeutic Potential of N-Acetylcysteine in Lung Silicosis? Cover

What is a Therapeutic Potential of N-Acetylcysteine in Lung Silicosis?

Open Access
|Dec 2021

References

  1. 1. Greenberg MI, Waksman J, Curtis J. Silicosis: a review. Dis Mon 2007; 53 (8): 394-416.10.1016/j.disamonth.2007.09.02017976433
  2. 2. Pollard KM. Silica, Silicosis, and Autoimmunity. Front Immunol 2016; 7: 97.10.3389/fimmu.2016.00097478655127014276
  3. 3. Barnes H, Goh NSL, Leong TL, Hoy R. Silica associated lung disease: An old world exposure in modern industries. Respirology 2019; 24 (12): 1165-75.10.1111/resp.1369531517432
  4. 4. Adamcakova J, Mokra D. New Insights into Pathomechanisms and Treatment Possibilities for Lung Silicosis. Int J Mol Sci 2021; 22 (8): 4162.10.3390/ijms22084162807289633920534
  5. 5. Schwalfenberg GK. N-Acetylcysteine: A Review of Clinical Usefulness (an Old Drug with New Tricks). J Nutr Metab 2021; 2021: 9949453.10.1155/2021/9949453821152534221501
  6. 6. Vallyathan V, Castranova V, Pack D, Leonard S, Shumaker J, Hubbs AF, Shoemaker DA, Ramsey DM, Pretty JR, McLaurin JL, et al. Freshly fractured quartz inhalation leads to enhanced lung injury and inflammation. Potential role of free radicals. Am J Respir Crit Care Med 1995; 152 (3): 1003-9.10.1164/ajrccm.152.3.76637757663775
  7. 7. Hamilton RF Jr, Thakur SA, Holian A. Silica binding and toxicity in alveolar macrophages. Free Radic Biol Med 2008; 44 (7): 1246-58.10.1016/j.freeradbiomed.2007.12.027268095518226603
  8. 8. Porter DW, Ye J, Ma J, Barger M, Robinson VA, Ramsey D, McLaurin J, Khan A, Landsittel D, Teass A, Castranova V. Time course of pulmonary response of rats to inhalation of crystalline silica: NF-kappa B activation, inflammation, cytokine production, and damage. Inhal Toxicol 2002; 14 (4): 349-67.10.1080/0895837025287099812028809
  9. 9. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF- B signaling. Cell Res 2011; 21 (1): 103-15.10.1038/cr.2010.178319340021187859
  10. 10. Harijith A, Ebenezer DL, Natarajan V. Reactive oxygen species at the crossroads of inflammasome and inflammation. Front Physiol 2014; 5: 352.10.3389/fphys.2014.00352417932325324778
  11. 11. Seo MS, Kim JK, Lim Y, Kang SW, Cho YJ, Lee WK, Kim HJ, Cho KK, Lee KH, Rhee SG. Rapid degradation of PrxI and PrxII induced by silica in Rat2 cells. Biochem Biophys Res Commun 1999; 265 (2): 541-4.10.1006/bbrc.1999.170910558905
  12. 12. Biswas R, Bunderson-Schelvan M, Holian A. Potential role of the inflammasome-derived inflamma tory cytokines in pulmonary fibrosis. Pulm Med 2011; 2011: 105707.10.1155/2011/105707310930921660282
  13. 13. Hu S, Zhao H, Al-Humadi NH, Yin XJ, Ma JK. Silica-induced apoptosis in alveolar macrophages: evidence of in vivo thiol depletion and the activation of mitochondrial pathway. J Toxicol Environ Health A 2006; 69 (13): 1261-84.10.1080/1528739050036187516754540
  14. 14. Kim KH, Lee MS. Autophagy--a key player in cellular and body metabolism. Nat Rev Endocrinol 2014; 10 (6): 322-37.10.1038/nrendo.2014.3524663220
  15. 15. Zhao H, Wang Y, Qiu T, Liu W, Yao P. Autophagy, an important therapeutic target for pulmonary fibrosis diseases. Clin Chim Acta 2020; 502: 139-47.10.1016/j.cca.2019.12.01631877297
  16. 16. Adamcakova J, Mokra D. Herbal compounds in the treatment of pulmonary silicosis. Physiol Res 2021; 70 (Suppl 1): xxx (accepted for publication).10.33549/10.33549/physiolres.934817
  17. 17. Huang H, Chen M, Liu F, Wu H, Wang J, Chen J, Liu M, Li X. N-acetylcysteine therapeutically protects against pulmonary fibrosis in a mouse model of silicosis. Biosci Rep 2019; 39: BSR20190681.10.1042/BSR20190681663945831273057
  18. 18. Aldini G, Altomare A, Baron G, Vistoli G, Carini M, Borsani L, Sergio F. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res 2018; 52 (7): 751-62.10.1080/10715762.2018.146856429742938
  19. 19. Tenório MCDS, Graciliano NG, Moura FA, Oliveira ACM, Goulart MOF. N-Acetylcysteine (NAC): Impacts on Human Health. Antioxidants (Basel) 2021; 10 (6): 967.10.3390/antiox10060967823402734208683
  20. 20. Calverley P, Rogliani P, Papi A. Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. Drug Saf 2021; 44 (3): 273-90.10.1007/s40264-020-01026-y789273333326056
  21. 21. Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000; 16 (2): 253-62.10.1034/j.1399-3003.2000.16b12.x
  22. 22. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000; 22 (2): 209-21.10.1016/S0149-2918(00)88479-9
  23. 23. Hansen NC, Skriver A, Brorsen-Riis L, Balsløv S, Evald T, Maltbaek N, Gunnersen G, Garsdal P, Sander P, Pedersen JZ, et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 1994; 88 (7): 531-5.10.1016/S0954-6111(05)80337-3
  24. 24. Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, Yao WZ, Ma LJ, Li X, Raiteri L, Sardina M, Gao Y, Wang BS, Zhong NS; PANTHEON study group. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomized, double-blind placebo-controlled trial. Lancet Respir Med 2014; 2 (3): 187-94.10.1016/S2213-2600(13)70286-8
  25. 25. Tse HN, Raiteri L, Wong KY, Yee KS, Ng LY, Wai KY, Loo CK, Chan MH. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest 2013; 144 (1): 106-18.10.1378/chest.12-235723348146
  26. 26. Johnson K, McEvoy CE, Naqvi S, Wendt C, Reilkoff RA, Kunisaki KM, Wetherbee EE, Nelson D, Tirouvanziam R, Niewoehner DE. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis 2016; 11: 799-807.10.2147/COPD.S102375
  27. 27. Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G; Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370 (22): 2093-101.10.1056/NEJMoa1401739411666424836309
  28. 28. Oldham JM, Ma SF, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, Valenzi E, Witt L, Lee C, Vij R, Huang Y, Strek ME, Noth I; IPFnet Investigators. TOLLIP, MUC5B, and the Response to NAcetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2015; 192 (12): 1475-82.10.1164/rccm.201505-1010OC473172326331942
  29. 29. Mokra D, Tonhajzerova I, Pistekova H, Visnovcova Z, Drgova A, Mokry J, Calkovska A. Car dio -vascular effects of N-acetylcysteine in meconium-induced acute lung injury. Adv Exp Med Biol 2015; 832: 35-43.10.1007/5584_2014_425300682
  30. 30. Meyer A, Buhl R, Kampf S, Magnussen H. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am J Respir Crit Care Med 1995; 152 (3): 1055-60.10.1164/ajrccm.152.3.76637837663783
  31. 31. Niemi TT, Munsterhjelm E, Pöyhiä R, Hynninen MS, Salmenperä MT. The effect of N-acetylcysteine on blood coagulation and platelet function in patients undergoing open repair of abdominal aortic aneurysm. Blood Coagul Fibrinolysis 2006; 17 (1): 29-34.10.1097/01.mbc.0000195922.26950.8916607076
  32. 32. Chiew AL, Gluud C, Brok J, Buckley NA. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev 2018; 2 (2): CD003328.10.1002/14651858.CD003328.pub3649130329473717
  33. 33. Yeh IJ, Wang TY, Lin JC, Lin TJ, Chang JS, Yen MC, Liu YH, Wu PL, Chen FW, Shih YL, Peng CY. Optimal Regimen of N-Acetylcysteine on Chromium-Induced Renal Cell Damage. Metabolites 2019; 9 (9):172.10.3390/metabo9090172678039631466266
  34. 34. Ooi SL, Green R, Pak SC. N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence. Biomed Res Int 2018; 2018: 2469486.10.1155/2018/2469486621790030426004
  35. 35. Cuzzocrea S, Mazzon E, Costantino G, Serraino I, Dugo L, Calabrò G, Cucinotta G, De Sarro A, Caputi AP. Beneficial effects of n-acetylcysteine on ischaemic brain injury. Br J Pharmacol 2000; 130 (6): 1219–26.10.1038/sj.bjp.0703421157218110903958
  36. 36. Crupi R, Gugliandolo E, Siracusa R, Impellizzeri D, Cordaro M, Di Paola R, Britti D, Cuzzocrea S. N-acetyl-L-cysteine reduces Leishmania amazonensis-induced inflammation in BALB/c mice. BMC Vet Res 2020; 16 (1): 13.10.1186/s12917-020-2234-9695869431931804
  37. 37. Poncin S, Colin IM, Decallonne B, Clinckspooor I, Many MC, Denef JF, Gérard AC. N-acetylcysteine and 15 deoxy-{delta}12,14-prostaglandin J2 exert a protective effect against autoimmune thyroid destruction in vivo but not against interleukin-1{alpha}/interferon {gamma}-induced inhibitory effects in thyrocytes in vitro. Am J Pathol 2010; 177 (1): 219-28.10.2353/ajpath.2010.091253289366520489149
  38. 38. Jorge-Aarón RM, Rosa-Ester MP. N-acetylcysteine as a potential treatment for COVID-19. Future Microbiol 2020; 15: 959-62.10.2217/fmb-2020-0074735941832662664
  39. 39. Poe FL, Corn J. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2. Med Hypotheses 2020; 143: 109862.10.1016/j.mehy.2020.109862726108532504923
  40. 40. Mokra D, Drgova A, Mokry J, Antosova M, Durdik P, Calkovska A. N-acetylcysteine effectively diminished meconium-induced oxidative stress in adult rabbits. J Physiol Pharmacol 2015; 66 (1): 101-10.
  41. 41. Mokra D, Drgova A, Petras M, Mokry J, Antosova M, Calkovska A. N-acetylcysteine alleviates the meconium-induced acute lung injury. Adv Exp Med Biol 2015; 832: 59-67.10.1007/5584_2014_725300685
  42. 42. Kopincová J, Mokrá D, Mikolka P, Kolomazník M, Čalkovská A. N-acetylcysteine advancement of surfactant therapy in experimental meconium aspiration syndrome: possible mechanisms. Physiol Res 2014; 63 (Suppl 4): S629-42.10.33549/physiolres.93293825669694
  43. 43. Mikolka P, Kopincova J, Mikusiakova LT, Kosutova P, Calkovska A, Mokra D. Antiinflammatory Effect of N-Acetylcysteine Combined with Exogenous Surfactant in Meconium-Induced Lung Injury. Adv Exp Med Biol 2016; 934: 63-75.10.1007/5584_2016_1527283193
  44. 44. Barrett EG, Johnston C, Oberdörster G, Finkelstein JN. Antioxidant treatment attenuates cytokine and chemokine levels in murine macrophages following silica exposure. Toxicol Appl Pharmacol 1999; 158 (3): 211-20.10.1006/taap.1999.871610438654
  45. 45. Kang JL, Go YH, Hur KC, Castranova V. Silica-induced nuclear factor-kappaB activation: involvement of reactive oxygen species and protein tyrosine kinase activation. J Toxicol Environ Health A 2000; 60 (1): 27-46.10.1080/00984100015657410832616
  46. 46. Hu S, Zhao H, Yin XJ, Ma JK. Role of mitochondria in silica-induced apoptosis of alveolar macrophages: inhibition of apoptosis by rhodamine 6G and N-acetyl-L-cysteine. J Toxicol Environ Health A 2007; 70 (17): 1403-15.10.1080/1528739070125199017687726
  47. 47. Li N, Shi F, Wang X, Yang P, Sun K, Zhang L, Hao X, Li X, Li J, Jin Y. Silica dust exposure induces pulmonary fibrosis through autophagy signaling. Environ Toxicol 2021; 36 (7): 1269-77.10.1002/tox.2312433720480
  48. 48. Zhang H, Yin G, Jiang H, Zhang C. High-dose N-acetylcysteine decreases silica-induced lung fibrosis in the rat. J Int Med Res 2013; 41 (4): 1179-86.10.1177/030006051348850323771710
  49. 49. Zhang L, He YL, Li QZ, Hao XH, Zhang ZF, Yuan JX, Bai YP, Jin YL, Liu N, Chen G, Yun X, Yao SQ. N-acetylcysteine alleviated silica-induced lung fibrosis in rats by down-regulation of ROS and mitochondrial apoptosis signaling. Toxicol Mech Methods 2014; 24 (3): 212-9.10.3109/15376516.2013.87997424392833
  50. 50. Xiao Y, Xia H, Zhu L, Li X, Chen R, Yin X, Jiang Z, Feng L, Chen J, Yu M, Lou J, Zhang X. Study on the therapeutic effects of tetrandrine combined with N-acetylcysteine on experimental silicosis of rats (article in Chinese). Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2015; 33 (7): 519-22.
  51. 51. Sun J, Song P, Wang Y, Chen Y. Clinical efficacy of acetylcysteine combined with tetrandrine tablets in the treatment of silicosis and the effect on serum IL-6 and TNF-alpha. Exp Ther Med 2019; 18 (5): 3383-8.10.3892/etm.2019.7966677725731602212
  52. 52. Guo X, Qi J, Li H, Xing Z. Clinical efficacy of acetylcysteine combined with tetrandrine tablets on patients with silicosis and its effect on exercise tolerance and pulmonary function. Exp Ther Med 2020; 20 (2): 1285-90.10.3892/etm.2020.8858738856732765668
  53. 53. Zhang J, Wang Y, Zhang S, Li J, Fang H. Effects of tetrandrine combined with acetylcysteine on exercise tolerance, pulmonary function and serum TNF- β1 and MMP-7 in silicosis patients. Exp Ther Med 2020; 19 (3): 2195-201.10.3892/etm.2020.8431702722932104284
  54. 54. Xie QM, Tang HF, Chen JQ, Bian RL. Pharmacological actions of tetrandrine in inflammatory pulmonary diseases. Acta Pharmacol Sin 2002; 23 (12): 1107-13.
  55. 55. Bhagya N, Chandrashekar KR. Tetrandrine--A molecule of wide bioactivity. Phytochemistry 2016; 125: 5-13.10.1016/j.phytochem.2016.02.00526899361
DOI: https://doi.org/10.2478/acm-2021-0011 | Journal eISSN: 1338-4139 (formerly 1335-8421) | Journal ISSN: 1335-8421
Language: English
Page range: 80 - 89
Submitted on: Oct 29, 2021
Accepted on: Nov 29, 2021
Published online: Dec 27, 2021
Published in print: Dec 1, 2021
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 3 issues per year

© 2021 Adamcakova Jana, Mokra Daniela, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.